Andere Sprachen Can-Fite BioPharma Ltd.

Aktien

A0X911

IL0010944739

CANF

Markt geschlossen - TEL AVIV STOCK EXCHANGE Andere Börsenplätze 16:24:51 20.05.2024			% 5 Tage	% 1. Jan.
2,9 ^ILa	0,00 %		+7,41 %	+11,54 %

12.05.	Transcript : Can-Fite BioPharma Ltd. - Special Call
09.05.	Can-Fite BioPharma Ltd. gibt bekannt, dass die FDA die IND-Zulassung für Namodenoson zur Behandlung von MASH-Patienten in einer Phase-IIb-Studie erteilt hat	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Can Fite BioPharma : Immediate Report	13.05.
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	13.05.
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	10.05.
Can Fite BioPharma : FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09.05.
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09.05.
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09.05.
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	06.05.
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	06.05.
LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL	26.04.
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	25.04.
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	16.04.
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15.04.
Can Fite BioPharma : Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15.04.
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	03.04.
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	03.04.
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	03.04.
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV	01.04.
Can Fite BioPharma : 20F FOR 2023	28.03.
Can-Fite Biopharma Ltd. Announces Clinical Update	28.03.
Can-Fite Reports 2023 Financial Results and Clinical Update	28.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Can-Fite BioPharma Ltd.

Aktien

A0X911

IL0010944739

CANF

Andere Sprachen

Filter